Non-small cell lung cancer
Drug research and approvals for non-small cell lung cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,311 studies of non-small cell lung cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 314 drug trials for it since 2013, FDA has 39 approved and 18 open orphan designations naming it, and the EU has 14 authorised medicines for it.
- Recruiting worldwide: 1,311
- Trials authorized in Canada: 314
- FDA orphan approvals: 39
- EU medicines: 14
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
- Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA)NCT07938385 · Not reported · Royal Marsden NHS Foundation Trust · starts May 20, 2022
- Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based…NCT07933055 · Phase 1 / Phase 2 · Txinno Bioscience Inc. · starts Oct 8, 2026
- Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNANCT07921888 · Not reported · Eun Hye Lee · starts Sep 28, 2026
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic…NCT07911449 · Phase 2 · Cho Ray Hospital · starts Feb 27, 2026
- Patient Needs and Preferences for NSCL Cancer Treatment MonitoringNCT07909343 · Not reported · European Institute of Oncology · starts Sep 22, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Development and Utilization of an Integrated Clinical Genomic DatabaseNCT07911267 · Not reported · Samsung Medical Center · starts Dec 6, 2024
Approved 24 of 37
- DocetaxelTubulin inhibitor
- PaclitaxelTubulin inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- PemetrexedThymidylate synthase inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- OsimertinibEpidermal growth factor receptor erbB1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- GefitinibEpidermal growth factor receptor erbB1 inhibitor
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- AfatinibEpidermal growth factor receptor erbB1 inhibitor
- CrizotinibHepatocyte growth factor receptor inhibitor
- TislelizumabProgrammed cell death protein 1 inhibitor
- RamucirumabVascular endothelial growth factor receptor 2 inhibitor
- TremelimumabCytotoxic T-lymphocyte protein 4 inhibitor
- LazertinibEpidermal growth factor receptor erbB1 inhibitor
- AlectinibALK tyrosine kinase receptor inhibitor
- CapmatinibHepatocyte growth factor receptor inhibitor
- SotorasibGTPase KRas inhibitor
- LorlatinibALK tyrosine kinase receptor inhibitor
- DacomitinibEpidermal growth factor receptor erbB1 inhibitor
Phase 3 12 of 133
- CarboplatinDNA inhibitor
- CisplatinDNA inhibitor
- VinorelbineTubulin inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- SintilimabProgrammed cell death protein 1 antagonist
- IcotinibEpidermal growth factor receptor erbB1 inhibitor
- AumolertinibEpidermal growth factor receptor erbB1 inhibitor
- ToripalimabProgrammed cell death protein 1 antagonist
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
- FirmonertinibEpidermal growth factor receptor erbB1 inhibitor
Phase 2 12 of 282
- VorinostatHistone deacetylase 1 inhibitor
- TrametinibDual specificity mitogen-activated protein kinase kinase 2 inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- BinimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- Bortezomib26S proteasome inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- EnvafolimabProgrammed cell death 1 ligand 1 binding agent
- ItraconazoleCytochrome P450 51 inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- NimotuzumabEpidermal growth factor receptor erbB1 inhibitor
Phase 1 or earlier 12 of 193
- SirolimusFK506-binding protein 1A inhibitor
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- Fludarabine
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- AldesleukinInterleukin-2 receptor agonist
- BelinostatHistone deacetylase inhibitor
- BerzosertibSerine-protein kinase ATR inhibitor
- CarotuximabEndoglin inhibitor
- BBP-398
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- VancomycinPeptidoglycan inhibitor
- GilteritinibTyrosine-protein kinase receptor FLT3 inhibitor
How its trials ended
5,613 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 1,514 whose ending is known, 27% met their primary endpoint, 10% missed it and 63% stopped early.
- Ongoing1,61429%
- Completed, result not reported1,61129%
- Status unknown87416%
- Stopped: other or unclear4278%
- Met its primary endpoint4057%
- Stopped: enrollment or feasibility2474%
- Missed its primary endpoint1543%
- Stopped: sponsor or business decision1533%
- Stopped: lack of efficacy761%
- Stopped: funding311%
- Stopped: safety21<1%
| Oct 27, 2026 | Luna-2: a phase II randomized trial of LND101 for fecal microbiota transplantation in combination with immune checkpoint blockade and chemotherapy in…LND101 | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Pending |
| Oct 22, 2026 | Rosetta LUNG-220: a phase 2, open-label, multicenter, multi-arm platform study evaluating pumitamig and other novel neoadjuvant regimens in participants with…Pumitamig (BMS-986545; BNT327) | Bristol-Myers Squibb | Pending |
| Oct 15, 2026 | A phase 3 open label randomized study of telisotuzumab adizutecan compared to standard of care in subjects with previously treated, EGFR wildtype, locally…Telisotuzumab adizutecan (ABBV-400) | AbbVie | Pending |
| Oct 9, 2026 | A phase 3, open-label study of ivonescimab vs durvalumab as consolidation therapy in patients with locally advanced, unresectable NSCLC (stage iii) who have…Ivonescimab | Summit Therapeutics | Pending |
| Sep 11, 2026 | A phase III, randomized, open-label study of izalontamab brengitecan (BMS-986507) in combination with osimertinib versus osimertinib monotherapy or osimertinib…Izalontamab brengitecan (BMS-986507) / Tagrisso (osimertinib) | Bristol-Myers Squibb | Ongoing |
| Jun 30, 2026 | A global, multicentre, phase II platform study of datopotamab deruxtecan (dato-dxd)-based combinations in adult participants with TROP2 nmr-positive non-small…Datopotamab deruxtecan / Durvalumab / Carboplatin | AstraZeneca Pharmaceuticals | Pending |
| Jun 25, 2026 | An interventional, phase 1 b, double-blind, randomized, sponsor-open, 2-arm study to investigate the effect of ponsegromab on skeletal muscle mass and physical…Ponsegromab (PF-06946860) | Pfizer | Pending |
| Jun 2, 2026 | A phase III, randomized, open-label study evaluating the efficacy and safety of divarasib compared with investigator’s choice of immunotherapy or observation…Divarasib (GDC-6036; RO7435846) / Pembrolizumab / Nivolumab | Roche | Ongoing |
| May 22, 2026 | A multicenter, first-in-human, dose escalation and optimization phase I/IIa study to investigate safety, tolerability, pharmacokinetics, and efficacy of the…TUB-040 | Tubulis GmbH | Pending |
| May 12, 2026 | An interventional, open-label, phase 2 study to investigate the safety and efficacy of PF-08634404 monotherapy or in combination in adult participants with…PF-08634404 (SSGJ-707) / Carboplatin / Paclitaxel / Pemetrexed | Pfizer | Pending |
| Sep 9, 2026 | HyrnuoTreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2… | Bayer HealthCare Pharmaceuticals Inc. | Approved |
| Jul 22, 2026 | JideytroTreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1… | Nuvalent, Inc. | Approved |
| Nov 19, 2025 | HyrnuoTreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2… | Bayer HealthCare Pharmaceuticals Inc. | Approved |
| Jun 11, 2025 | IbtroziTreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) | Nuvation Bio Inc. | Approved |
| Sep 25, 2024 | TagrissoTreatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not… | AstraZeneca Pharmaceuticals LP | Approved |
| Apr 18, 2024 | AlecensaAdjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer… | Hoffmann-La Roche, Inc. (c/o Genentech, Inc.) | Approved |
| Feb 16, 2024 | TagrissoIn combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or… | AstraZeneca Pharmaceuticals LP | Approved |
| Nov 15, 2023 | AugtyroTreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) | Bristol Myers Squibb Company | Approved |
| Oct 11, 2023 | BraftoviIn combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E… | Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.) | Approved |
| Sep 7, 2023 | XalkoriTreatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or… | Pfizer, Inc. | Approved |
| Dec 12, 2022 | KrazatiTreatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an… | Bristol-Myers Squibb Company | Approved |
| Sep 21, 2022 | RetevmoTreatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection… | Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| Sep 15, 2021 | ExkivityTreatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor… | Takeda Development Center Americas, Inc. | Approved |
| May 28, 2021 | LumakrasTreatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an… | Amgen Inc. | Approved |
| Mar 3, 2021 | LorbrenaTreatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive… | Pfizer, Inc. | Approved |
| Jan 13, 2025 | AugtyroRepotrectinib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Jan 5, 2024 | KrazatiAdagrasib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Sep 15, 2023 | TevimbraTislelizumab | Beone Medicines Ireland Limited | EMA ↗ |
| Feb 16, 2022 | TepmetkoTepotinib | Merck Europe B.V. | EMA ↗ |
| Jan 6, 2022 | LumykrasSotorasib | Amgen Europe B.V. | EMA ↗ |
| Sep 21, 2018 | ImfinziDurvalumab | AstraZeneca AB | EMA ↗ |
| Sep 20, 2018 | MektoviBinimetinib | Pierre Fabre Medicament | EMA ↗ |
| Feb 1, 2016 | TagrissoOsimertinib | AstraZeneca AB | EMA ↗ |
| Jan 18, 2016 | Pemetrexed AccordPemetrexed · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 18, 2016 | Armisarte (previously Pemetrexed Actavis)Pemetrexed | Actavis Group PTC ehf | EMA ↗ |
| Nov 19, 2015 | Pemetrexed Pfizer (previously Pemetrexed Hospira)Pemetrexed · generic | Pfizer Europe MA EEIG | EMA ↗ |
| Nov 21, 2014 | VargatefNintedanib | Boehringer Ingelheim International GmbH | EMA ↗ |
| Sep 25, 2013 | GiotrifAfatinib | Boehringer Ingelheim International GmbH | EMA ↗ |
| Sep 19, 2005 | TarcevaErlotinib | Cheplapharm Registration GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA